Advaxis to Present at 2017 BIO International Convention
June 16 2017 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company
developing cancer immunotherapies, today announced that Ranya
Dajani, Vice President, Business Development, will present a
company overview at the 2017 Biotechnology Innovation
Organization’s (BIO) International Convention in San Diego, CA.
Event: 2017 BIO International ConventionPresentation
Date: June 20, 2017Presentation Time: 4 p.m.
PTLocation: San Diego Convention Center, Theater 2
The BIO International Convention is the world’s largest
gathering among the biotechnology industry attended by more than
16,000 biotechnology professionals from more than 3,100 companies.
The convention will highlight innovation in biotech with keynote
speakers, fireside chats, partnering meetings, company
presentations and exhibitors from all fields.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a late-stage
biotechnology company developing multiple cancer immunotherapies
based on its proprietary Lm Technology. Lm Technology, using
bioengineered live attenuated Listeria monocytogenes (Lm) bacteria,
is the only known cancer immunotherapy agent shown in preclinical
studies to both generate cancer fighting T cells directed against
cancer antigens and neutralize Tregs and myeloid-derived suppressor
cells (MDSCs) that protect the tumor microenvironment from
immunologic attack and contribute to tumor growth. Advaxis’ lead Lm
Technology™ immunotherapies axalimogene filolisbac and ADXS-DUAL
target HPV-associated cancers and are in clinical trials for
invasive and metastatic cervical cancer, head and neck cancer and
anal cancer. The FDA has granted axalimogene filolisbac orphan drug
designation for each of these three clinical settings, as well as
Fast Track designation for adjuvant therapy for HRLACC patients and
a SPA for the Phase 3 AIM2CERV trial in HRLACC patients.
Axalimogene filolisbac has also been classified as an advanced
therapy medicinal product for the treatment of cervical cancer by
the EMA’s CAT. Advaxis has two additional immunotherapy products:
ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid
tumors, in human clinical development. In addition, Advaxis and
Amgen are developing ADXS-NEO, an investigational cancer
immunotherapy treatment designed to activate a patient's immune
system to respond against the unique mutations, or neoepitopes,
contained in and identified from each individual patient's tumor,
with plans to enter the clinic in 2017.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop the next generation of cancer immunotherapies,
and the safety and efficacy of Advaxis’ proprietary
immunotherapies, axalimogene filolisbac and ADXS-DUAL. These
forward-looking statements are subject to a number of risks
including the risk factors set forth from time to time in Advaxis’
SEC filings including, but not limited to, its report on Form 10-K
for the fiscal year ended October 31, 2016, which is available at
http://www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law.
You are cautioned not to place undue reliance on any
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170616005120/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
Affairsheber@advaxis.comorMedia Contact:JPA Health
CommunicationsDavid Connolly, 617-657-1301dconnolly@jpa.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024